What is the role of mesylate in the treatment of dermatofibrosarcoma protuberans (DFSP)?

Updated: Mar 06, 2020
  • Author: Raman K Madan, MD; Chief Editor: William D James, MD  more...
  • Print

Although medical therapy is not a first-line treatment for localized dermatofibrosarcoma protuberans (DFSP), the approved molecular-targeted drug, imatinib mesylate, is an effective oral medication for unresectable, recurrent, and/or metastatic DFSP.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!